The marketing authorisation for Ariclaim has been withdrawn at the request of the marketing authorisation holder.
Ariclaim : EPAR - Summary for the public (PDF/472.53 KB)
First published: 16/07/2009
Last updated: 07/08/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Eli Lilly Nederland B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
09/12/2016 Ariclaim - EMEA/H/C/000552 - N/0066
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Treatment of diabetic peripheral neuropathic pain.
Ariclaim is indicated in adults.